Market Place
Sourcing Support
Citius Oncology Launches LYMPHIR for CTCL in U.S
01 Dec 2025 //
PR NEWSWIRE
Citius Oncology to Showcase Pipeline at 67th ASH Meeting
25 Nov 2025 //
PR NEWSWIRE
Citius Oncology Advances LYMPHIR™ Commercial Launch With Verix
21 Nov 2025 //
PR NEWSWIRE BIO
Citius Oncology Inks U.S. Distribution Deal With Mckesson
20 Oct 2025 //
PR NEWSWIRE
Citius Pharma, Citius Oncology To Join October 2025 Conferences
17 Oct 2025 //
PR NEWSWIRE
Citius Signs Exclusive Commercialization Agreement with Eversana
16 Oct 2025 //
PR NEWSWIRE
Citius Oncology Expands Lymphir Access in Southern Europe
07 Oct 2025 //
PR NEWSWIRE
Citius Oncology Closes $9.0M Direct Offering & Private Placement
11 Sep 2025 //
PR NEWSWIRE
Citius Oncology Price $9.0M Direct Offering and Private Placement
09 Sep 2025 //
PR NEWSWIRE
Citius Oncology Use AI to Boost Performance Before LYMPHIR Launch
23 Aug 2025 //
PR NEWSWIRE
Citius Oncology Reports Q3 2025 Financial Results & Update
12 Aug 2025 //
PR NEWSWIRE
Rare Disease Clinical Progress Boosts Long-Term Revenue Potential
07 Aug 2025 //
PR NEWSWIRE
Citius Oncology Announces Closing of $9.0 Million Public Offering
17 Jul 2025 //
PR NEWSWIRE
Citius Oncology Prices $9.0 Million Public Offering
16 Jul 2025 //
PR NEWSWIRE
Citius Oncology Expands LYMPHIR Distribution with Cencora
15 Jul 2025 //
PR NEWSWIRE
Citius Oncology partners with Cardinal Health For Distribution
09 Jun 2025 //
PR NEWSWIRE
Citius Oncology Reports Q2 2025 Financials and Business Update
14 May 2025 //
PR NEWSWIRE
Citius Oncology Reports Q1 FY25 Results, Provides Update
14 Feb 2025 //
PR NEWSWIRE
Citius Pharma Announces Permanent J-Code for LYMPHIR by CMS
06 Feb 2025 //
PR NEWSWIRE
Citius Plans LYMPHIR Commercial Launch In First Half Of 2025
07 Jan 2025 //
PR NEWSWIRE
Citius Oncology Engages Jefferies To Explore Strategic Alternatives
06 Jan 2025 //
PR NEWSWIRE
Citius Oncology Reports 2024 Financial Results and Business Update
27 Dec 2024 //
PR NEWSWIRE
Citius Pharma Announces Promising Pembrolizumab Trial Results
11 Nov 2024 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.